The following are some of the biotech companies that reported quarterly results and provided an update on their pipeline progress on Thursday.
1. Aerie Pharmaceuticals Inc. (AERI) expects to initiate a phase III registrational study for AR-15512 in dry eye during the second quarter of 2022.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com